Veterinary practice and research converge to advance joint health solutions. | Courtesy Contura VetOver the pastdecadeintra-articular 2.5% polyacrylamide hydrogel (2.5%iPAAG,Arthramid) has gained wide clinical adoption in equine and canine practice, with more than 300,000 horses and countless dogs treated worldwide. Manyshowlong-lasting improvement after one injection, butConturaVet has continued to invest in rigorous scientific research to understand the mechanisms, safety, and long-term outcomes associated with 2.5%iPAAG.Unlike traditional joint therapies such as corticosteroidswhich provide transient symptom relief without addressing the underlying synovial pathology2.5%iPAAGintegrates into the synovial membrane, improving its structural integrity and function. Restoring joint mechanics supports normal function downstream.Research Pipeline Through 2025A hallmark ofConturaVets approach is its commitment to advancing the science behind 2.5%iPAAG. By 2025s end, peer-reviewed presentations will span equine, canine, and human medicine.International Cartilage Regeneration & Joint Preservation Society World CongressOctoberThe Symptom and Disease Modifying Effects of Intra-articular (IA) 2.5% Polyacrylamide Gel in an Equine Preclinical Osteoarthrosis ModelSynovial Transcriptomic Response to IA 2.5% Polyacrylamide Hydrogel in an Equine Osteoarthritis (OA) ModelShear Stiffness of Equine Synovial Membrane in OA and Response to Polyacrylamide Hydrogel TreatmentNine human-focused presentations withArthrosamid (human product.Presenters: Erin Contino, DVM, Dipl. ACVSMR; LynnPezzanite, DVM, MS, PhD, Dipl. ACVS; Markus Wimmer, PhDAmerican College of Veterinary Surgeons Surgery SummitOctober2.5% Polyacrylamide Gel in Canine Elbow OA (084-Day Data)Owner-Reported Outcomes: IA 2.5%iPAAGInjection is Well Tolerated and Reduces OA Signs in Dogs2.5% Hydrogel in an Equine OA ModelArthramid and the One Health Continuum: Translational Insights in SynovitisandOsteoarthritisPresenters: Katie Seabaugh, DVM, Dipl. ACVS, ACVSMR; Matthew Brunke, DVM, Dipl. AVSMR, CCAT; Lisa Fortier, DVM, PhD, Dipl. ACVS; and Courtney Campbell, DVM, Dipl. ACVS.AAEP ConventionDecemberRevolutionizing Equine Speed Events: The Global Therapeutic Impact of 2.5% Polyacrylamide HydrogelVeterinary Innovation Focus: What Sets 2.5%iPAAGPolyacrylamide Apart in Veterinary Medical DevicesRetrospective Analyses of Long-Term Use of 2.5%iPAAGin Thoroughbred Racehorses (701 horses) and Sport Horses (1,000 horses)Synovial Transcriptomic Response to Intra-Articular 2.5%iPAAGTherapy in Experimentally Induced Equine OAEvaluating Symptom- and Disease-Modifying Effects of 2.5%iPAAGin the Osteochondral Fragment Model for OAPresenters: Contino;Pezzanite; Wayne McIlwraith, BVSc, PhD, FRCVS, Dipl. ACVS, ECVS, ACVSMR; Marc Koene, DVM, IAVC/IVCA; Leigh de Clifford, BVSc,CertAVP,PGDipVPS, MRCVSTranslational ImpactThis growing body of evidence shows how 2.5%iPAAGcan alter jointdiseasescourse, support veterinarians decision-making, and inform human orthopedics.Many companies conclude research efforts once a product reaches market, says Michaela Arcaro, VP of Operations,ConturaVet. We are committed to expanding the scientific foundation ofArthramid andArthrosamid, ensuring veterinarians and physicians have access to robust, high-quality data to guide care.Through ongoing clinical studies and collaborative research across veterinary and human medicine, we are uncovering new insights into the pathophysiology and treatment of OA,she adds. The unique properties of 2.5%iPAAGoffer a novel therapeutic option (and) a valuable tool for advancing our understanding of OA mechanisms, progression, and response to treatment across species. This knowledge is helping reshape how OA is approachedfrom early diagnosis to long-term managementimproving outcomes for animals and humans.